Biomarker test for cervical, ovarian or endometrial cancer
| Reference number | |
| Coordinator | Uppsala universitet - Institutionen för immunologi, genetik och patologi |
| Funding from Vinnova | SEK 900 000 |
| Project duration | July 2016 - July 2017 |
| Status | Completed |
Important results from the project
The aim of the project is to perform a number of steps towards formulation and marketing of a diagnostic test for gynecological cancer (ovarian cancer, endometrial cancer and cervical cancer), based on the analysis of a number of proteins in a blood sample. A screening of 500 protein candidates have been performed and the effect of the top candidates have been replicated in an independent patient material. A discussion with FDA has been conducted to determine the requirements on multiplex protein assays as IVD.
Expected long term effects
A test for gynecological cancer would be of great importance in facilitating diagnosis and improving the care of in particular for women with ovarian cancer.
Approach and implementation
The project involves a comprehensive screening of protein candidates and a replication the most promising in independent patient material. It is based on PEA technology for multiplex protein analysis that has high specificity and sensitivity. The project is conducted in collaboration with OLINK Proteomics, that has special knowledge regarding this technology and an interest in developing this into an IVD test.